The aim of this article is to demonstrate extreme interindividual variability of piperacilin/tazobactam (PIP/TAZO) pharmacokinetics in critically ill morbidly obese patients and to emphasize the need for the practice of routine PIP/TAZO plasma concentrations measurement in order to ensure optimal efficacy and safety of antibiotic therapy.

Department of Clinical Microbiology and Antibiotic Surveillance Na Homolce Hospital Prague Czech Republic

Department of Clinical Pharmacy Na Homolce Hospital Prague Czech Republic

Department of Pharmacology Motol University Hospital and 2nd Faculty of Medicine Charles University Prague Czech Republic

Institute of Pharmacology General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Pfizer . Product Information. Tazocin (piperacillin/tazobactam). [Online] 2020 [cited in 2020]. Available from: https://www.pfizer.com/products/product‐detail/piperacillin_and_tazobactam

Sinnollareddy MJ, Roberts MS, Lipman J, Roberts JA. Beta‐lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol. 2012;39(6):489‐496. PubMed

Gonçalves‐Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of b‐lactams. Crit Care. 2011;15(5):206. PubMed PMC

Sadilová K, Halačová M, Černý D. Pharmacokinetic aspects of beta‐lactam antibiotic therapy in intensive care unit patients: a one‐center experience with TDM. Ceska Slov Farm. 2020;69(1):17‐23. PubMed

Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27‐36. PubMed PMC

Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive guidance for antibiotic dosing in obese adults. Pharmacotherapy. 2017;37(11):1415‐1431. PubMed

Suchánková H, Matušková Z, Lecianova A. Therapeutic drug monitoring of beta‐lactam antibiotics. Klin Mikrobiol Inf lék. 2017;23(1):4‐9. PubMed

Jung B, Mahul M, Breilh D, et al. Repeated piperacillin‐Tazobactam plasma concentration measurements in severely obese versus nonobese critically ill septic patients and the risk of under‐ and overdosing. Crit Care Med. 2017;45(5):470‐478. PubMed

Roberts J, Ulldemolins M, Roberts M, et al. Therapeutic drug monitoring of Beta‐lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36(4):332‐339. PubMed

Newman D, Scheetz MH, Adeyemi OA, et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother. 2007;41(10):1734‐1739. PubMed

The Renal Drug Handbook. 3rd ed. Oxford: Radcliffe Publishing Ltd; 2009. Tazocin (piperacillin/tazobactam); p. 703.

Sturm AW, Allen N, Rafferty DK, et al. Pharmacokinetic analysis of piperacillin administered with Tazobactam in critically ill, Morbidly Obese Surgical Patients. Pharmacotherapy. 2014;34(1):28‐35. PubMed

Deman H, Verhaegen J, Willems L, Spriet I. Dosing of piperacillin/tazobactam in a morbidly obese patient. J Antimicrob Chemother. 2012;67(3):782‐783. PubMed

Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010;35:156‐163. PubMed

Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis ‐ bolus versus continuous administration? Crit Care Med. 2009;37:926‐933. PubMed

Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin‐tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended‐infusion dosing strategy. Clin Infect Dis. 2007;44:357‐363. PubMed

Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589‐1596. PubMed

Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign guidelines committee including the pediatric subgroup: surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165‐228. PubMed PMC

Boselli E, Breilh D, Rimmelé T, et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator‐associated pneumonia. Crit Care Med. 2008;36:1500‐1506. PubMed